Human plasma-derived immunoglobulin G fractionated by an aqueous two-phase system, caprylic acid precipitation, and membrane chromatography has a high purity level and is free of detectable in vitro thrombogenic activity

Vox Sanguinis

Volumn 108, Issue 2, 2015, Pages 169-177

  Vargas, M ^a   Segura, Á ^a   Wu, Y W ^b   Herrera, M ^a   Chou, M L ^c   Villalta, M ^a   Leon G ^a   Burnouf, T ^b  

^a UNIVERSIDAD DE COSTA RICA   (Costa Rica)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Aqueous two phase system; Chromatography; Immunoglobulin; Plasma fractionation; Thrombogenicity

Indexed keywords

BLOOD CLOTTING FACTOR 10A; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN SUBCLASS; MACROGOL; OCTANOIC ACID; PHOSPHATE; PLASMIN; PREKALLIKREIN; THROMBIN; BENZOYL-ILE-GLU-GLY-ARG-P-NITROANILIDE; BLOOD CLOTTING FACTOR 12A; OCTANOIC ACID DERIVATIVE; OLIGOPEPTIDE; PROLYL-PHENYLALANYL-ARGININE-4-NITROANILIDE; VALYL-LEUCYL-LYSINE 4-NITROANILIDE;

ANALYTIC METHOD; ARTICLE; CHROMATOGRAPHY; ELECTROPHORESIS; FRACTIONATION; IMMUNOCHEMISTRY; IN VITRO STUDY; PLASMA; PRECIPITATION; PRIORITY JOURNAL; THROMBIN TIME; THROMBOGENICITY; BIOSYNTHESIS; CHEMISTRY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; ISOLATION AND PURIFICATION; PROCEDURES;

CAPRYLATES; CHEMICAL FRACTIONATION; CHROMATOGRAPHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR XIIA; HUMANS; IMMUNOGLOBULIN G; OLIGOPEPTIDES; PLASMA; THROMBIN;

EID: 84921310899     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/vox.12209     Document Type: Article

References (34)

1. Burnouf T: Recombinant plasma proteins. Vox Sang 2011; 100:68-83
2. Cheraghali AM, Abolghasemi H: Plasma fractionation, a useful means to improve national transfusion system and blood safety: Iran experience. Haemophilia 2009; 15:487-493
3. Cheraghali AM, Aboofazeli R: Economical impact of plasma fractionation project in Iran on affordability of plasma-derived medicines. Transfus Med 2009; 19:363-368
4. Farrugia A, Evers T, Falcou PF, et al.: Plasma fractionation issues. Biologicals 2009; 37:88-93
5. Park Q, Kim MJ, Lee J, et al.: Plasma fractionation in Korea: working towards self-sufficiency. Korean J Hematol 2010; 45:3-5
6. Vargas M, Segura A, Herrera M, et al.: Purification of IgG and albumin from human plasma by aqueous two phase system fractionation. Biotechnol Prog 2012; 28:1005-1011
7. Radosevich M, Burnouf T: Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance. Vox Sang 2010; 98:12-28
8. Anonymous: Octagam (Immune Globulin Intravenous (human) 5% Liquid Preparation: Market Withdrawal - Risk of Thromboembolic Events; in Administration UFaD, (ed). Bethesda, US Food and Drug Administration, 2010.
9. Anonymous: European Medicines Agency recommends suspension of Octagam in all EU member states. CHMP Recommendation Based on Risk of Thromboembolic Reactions. Report No.: EMA/CHMP/591722/2010.; in Agency EM, (ed). Sept 24, 2010, London, UK, European Medicines Agency, 2010.
10. Daniel GW, Menis M, Sridhar G, et al.: Immune globulins and thrombotic adverse events as recorded in a large administrative database in 2008 through 2010. Transfusion 2012; 52:2113-2121
11. Etscheid M, Breitner-Ruddock S, Gross S, et al.: Identification of kallikrein and FXIa as impurities in therapeutic immunoglobulins: implications for the safety and control of intravenous blood products. Vox Sang 2012; 102:40-46
12. Wolberg AS, Kon RH, Monroe DM, et al.: Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. Am J Hematol 2000; 65:30-34
13. Garcia M, Monge M, Leon G, et al.: Effect of preservatives on IgG aggregation, complement-activating effect and hypotensive activity of horse polyvalent antivenom used in snakebite envenomation. Biologicals 2002; 30:143-151
14. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227:680-685
15. Wu YW, Champagne J, Toueille M, et al.: Dedicated removal of immunoglobulin (Ig)A, IgM, and Factor (F)XI/activated FXI from human plasma IgG. Transfusion 2014; 54:169-178
16. Burnouf T: New approaches for manufacturing plasma derivatives. ISBT Sci Ser 9:160-167. doi: 10.1111/voxs.12099
17. Burnouf T: Modern plasma fractionation. Transfus Med Rev 2007; 21:101-117
18. Asenjo JA, Andrews BA: Aqueous two-phase systems for protein separation: a perspective. J Chromatogr A 2011; 1218:8826-8835
19. León G, Herrera M, Segura Á, et al.: Pathogenic mechanisms underlying adverse reactions induced by intravenous administration of snake antivenoms. Toxicon 2013; 76:63-76
20. John Looney R, Huggins J: Use of intravenous immunoglobulin G (IVIG). Best Pract Res Clin Haematol 2006; 19:3-25
21. Page M, Ling C, Dilger P, et al.: Fragmentation of therapeutic human immunoglobulin preparations. Vox Sang 1995; 69:183-194
22. Alving BM, Tankersley DL, Mason BL, et al.: Contact-activated factors: contaminants of immunoglobulins preparations with coagulant and vasoactive properties. J Lab Clin Med 1980; 96:334-346
23. ® manufacturing process. Immunotherapy 2011; 2(WMC002002):2011
24. Anonymous: Monograph on human normal immunoglobulin for intravenous administration (0918): 01/2012, European Pharmacopoeia, Strasbourg (France), Council of Europe, 2012.; in Commission EP, (ed). Strasbourg, France, Council of Europe European Department for the Quality of Medicines, 2012.
25. Jose M, Marzo N, Pons B, et al.: Flebogamma((R)) DIF (intravenous immunoglobulin) purification process effectively eliminates procoagulant activities. Biologicals 2013; 41:393-399
26. Funk MB, Gross N, Gross S, et al.: Thromboembolic events associated with immunoglobulin treatment. Vox Sang 2013; 105:54-64
27. Germishuizen WA, Gyure DC, Stubbings D, et al.: Quantifying the thrombogenic potential of human plasma-derived immunoglobulin products. Biologicals 2014; 42:260-270.
28. FDA-Workshop: Risk Mitigation Strategies to Address Potential Procoagulant Activity in Immune Globulin Products; in Administration FD, (ed) http://wwwfdagov/downloads/BiologicsBloodVaccines/NewsEvents/WorkshopsMeetingsConferences/UCM258022pdf. 2011.
29. Seifner A, Beck G, Bayer P, et al.: Assessment of immunoglobulin concentrates on thrombogenic activity by thrombin generation assay, prekallikrein activator assay, and size-exclusion chromatography. Transfusion 2014; 54:376-383
30. Johansson H-O, Karlström G, Tjerneld F, et al.: Driving forces for phase separation and partitioning in aqueous two-phase systems. J Chromatogr B Biomed Sci Appl 1998; 711:3-17
31. ® purification process to deplete thrombogenic factor XIa from plasma. Vox Sang 2013; 107:26-36
32. Dichtelmüller H, Rudnick D, Kloft M: Inactivation of lipid enveloped viruses by Octanoic acid treatment of immunoglobulin solution. Biologicals 2002; 30:135-142
33. Kempf C, Stucki M, Boschetti N: Pathogen inactivation and removal procedures used in the production of intravenous immunoglobulins. Biologicals 2007; 35:35-42
34. Burnouf T, Radosevich M: Reducing the risk of infection from plasma products: specific preventative strategies. Blood Rev 2000; 14:94-110